Obagi Medical Sold to Bridgepoint for $460M

June 1. Bridgepoint Group agreed to acquire Obagi Medical from Waldencast for $460 million, the UK investment firm announced this morning. The clinical skincare label's co-founders, Michel Brousset and Hind Sebti, are leaving the beauty conglomerate to join Bridgepoint alongside the brand.

Obagi Medical operates in the dermatologist-preferred lane: medical-grade retinols, vitamin C serums, post-procedure recovery systems. The brand skews clinical over cool, a category where distribution matters more than Instagram reach. Bridgepoint's move signals a bet on the doctor's-office channel, not the DTC beauty scramble.

Waldencast assembled a portfolio of beauty brands through acquisition over the past three years. Obagi Medical was one of the anchors. The departure of both co-founders alongside the sale is the tell here: when the founders leave with the brand, the marriage wasn't working. Bridgepoint gets a clinical skincare business with institutional credibility and two operators who built it.

The $460 million price tag sits below the multiples seen in prestige beauty M&A over the past two years, where brands with thinner margins and social traction commanded higher valuations. Obagi's value is in the dermatologist network and the repeat-customer rate, not the launch-day hype cycle. Different math.

Bridgepoint has backed beauty before: the firm held stakes in Elemis and PZ Cussons. The playbook leans toward operational scale, not creative repositioning. Obagi Medical likely stays Obagi Medical, just with better backend logistics and a clearer path to pharmacy retail expansion.

The deal is expected to close in Q3. No word yet on whether Waldencast plans to replace the founders internally or refocus the portfolio around its remaining brands.